Am­gen re­searchers con­firm the lack­lus­ter da­ta on the KRAS G12C drug AMG 510 re­port­ed at ES­MO — but they still have a long way to go ex­plor­ing op­tions

We learned at ES­MO that Am­gen’s star can­cer drug, the pi­o­neer­ing KRAS G12C play­er AMG 510, tend­ed to­ward the unim­pres­sive when ap­plied out­side non …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.